Page 65 - Read Online

Hung et al. Attenuation of liver stiffness by sorafenib

4. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a demonstration of feasibility and utility. Ultrasound Med Biol
translational success story. Gut 2015;64:830-41. 2005;31:1185-98.
5. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic 18. Friedrich-Rust M, Nierhoff J, Lupsor M, Sporea I, Fierbinteanu-
stellate cells. Semin Liver Dis 2001;21:397-416. Braticevici C, Strobel D, Takahashi H, Yoneda M, Suda T, Zeuzem
6. Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into S, Herrmann E. Performance of Acoustic Radiation Force Impulse
the antifibrotic effects of sorafenib on hepatic stellate cells and liver imaging for the staging of liver fibrosis: a pooled meta-analysis. J
fibrosis. J Hepatol 2010;53:132-44. Viral Hepat 2012;19:e212-9.
7. Kuo WL, Yu MC, Lee JF, Tsai CN, Chen TC, Chen MF. Imatinib 19. Nierhoff J, Chávez Ortiz AA, Herrmann E, Zeuzem S, Friedrich-Rust
mesylate improves liver regeneration and attenuates liver fibrogenesis M. The efficiency of acoustic radiation force impulse imaging for the
in CCL4-treated mice. J Gastrointest Surg 2012;16:361-9. staging of liver fibrosis: a meta-analysis. Eur Radiol 2013;23:3040-
8. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch 53.
M. Preclinical overview of sorafenib, a multikinase inhibitor that 20. European Association For The Study Of The Liver; European
targets both Raf and VEGF and PDGF receptor tyrosine kinase Organisation For Research And Treatment Of Cancer. EASL-
signaling. Mol Cancer Ther 2008;7:3129-40. EORTC clinical practice guidelines: management of hepatocellular
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de carcinoma. J Hepatol 2012;56:908-43.
Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta 21. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida
C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL,
I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK,
Bruix J; SHARP Investigators Study Group. Sorafenib in advanced Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF,
hepatocellular carcinoma. N Engl J Med 2008;359:378-90. Sarin SK. Asian Pacific Association for the Study of the Liver
10. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng consensus recommendations on hepatocellular carcinoma. Hepatol
J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Int 2010;4:439-74.
Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety 22. American Joint Committee on Cancer (AJCC). Cancer Staging
of sorafenib in patients in the Asia-Pacific region with advanced Manual. 7th ed. New York: Springer; 2009.
hepatocellular carcinoma: a phase III randomised, double-blind, 23. Frulio N, Laumonier H, Carteret T, Laurent C, Maire F, Balabaud C,
placebo-controlled trial. Lancet Oncol 2009;10:25-34. Bioulac-Sage P, Trillaud H. Evaluation of liver tumors using acoustic
11. Hong F, Chou H, Fiel MI, Friedman SL. Antifibrotic activity of radiation force impulse elastography and correlation with histologic
sorafenib in experimental hepatic fibrosis: refinement of inhibitory data. J Ultrasound Med 2013;32:121-30.
targets, dosing, and window of efficacy in vivo. Dig Dis Sci 24. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi
2013;58:257-64. G, Colombo M. Reproducibility of transient elastography in the
12. Deng YR, Ma HD, Tsuneyama K, Yang W, Wang YH, Lu FT, Liu evaluation of liver fibrosis in patients with chronic liver disease. Gut
CH, Liu P, He XS, Diehl AM, Gershwin ME, Lian ZX. STAT3- 2007;56:968-73.
mediated attenuation of CCl4-induced mouse liver fibrosis by the 25. Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive
protein kinase inhibitor sorafenib. J Autoimmun 2013;46:25-34. assessment of liver fibrosis. Ann Gastroenterol 2012;25:218-31.
13. Su TH, Shiau CW, Jao P, Liu CH, Liu CJ, Tai WT, Jeng YM, Yang 26. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT,
HC, Tseng TC, Huang HP, Cheng HR, Chen PJ, Chen KF, Kao Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie
JH, Chen DS. Sorafenib and its derivative SC-1 exhibit antifibrotic AW, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting
effects through signal transducer and activator of transcription 3 cirrhosis in patients with hepatitis C based on standard laboratory
inhibition. Proc Natl Acad Sci U S A 2015;112:7243-8. tests: results of the HALT-C cohort. Hepatology 2005;42:282-92.
14. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; 27. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y,
American Association for the Study of Liver Diseases. Liver biopsy. Xuan SY. Performance of the aspartate aminotransferase-to-platelet
Hepatology 2009;49:1017-44. ratio index for the staging of hepatitis C-related fibrosis: an updated
15. Asrani SK. Incorporation of noninvasive measures of liver fibrosis meta-analysis. Hepatology 2011;53:726-36.
into clinical practice: diagnosis and prognosis. Clin Gastroenterol 28. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of
Hepatol 2015;13:2190-204. aspartate aminotransferase to platelet ratio index and fibrosis-4 index
16. Nightingale K, Soo MS, Nightingale R, Trahey G. Acoustic radiation for detecting liver fibrosis in adult patients with chronic hepatitis B
force impulse imaging: in vivo demonstration of clinical feasibility. virus infection: a systemic review and meta-analysis. Hepatology
Ultrasound Med Biol 2002;28:227-35. 2015;61:292-302.
17. Fahey BJ, Nightingale KR, Nelson RC, Palmeri ML, Trahey 29. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment
GE. Acoustic radiation force impulse imaging of the abdomen: for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.

Hepatoma Research ¦ Volume 3 ¦ March 24, 2017 57